Thyroid gland development

Across TCGA cell cohorts, RNA activity of the Thyroid gland development pathway is significantly associated with the drug response of multiple features, with the LUNG_SCLC cohort showing a particularly strong set of associations.

The most reproducible pathway-associated features across cancer lineages are FS106, Midostaurin, and Ponatinib, each associated with the pathway in up to 1 cancer types. Since the analysis shows associations rather than directional relationships, both pathway-to-partner and partner-to-pathway views are reported.

Each partner is linked to its corresponding Q-omics profile. The box plot shows the strongest association, FS106 grouped by Thyroid gland development-low versus -high activity in LUNG_SCLC.

Pathway-associated features by consensus

Ranked by combined sampling and lineage consensus. X-score (pathway→partner) and Y-score (partner→pathway) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner feature	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
LUNG_SCLC	FS106 →	+0.509	+1.414	.015	.008	1	1
LUNG_SCLC	Midostaurin →	+0.970	+1.414	.016	.008	1	1
LUNG_SCLC	Ponatinib →	+0.919	+1.414	.007	.008	1	1
LUNG_SCLC	JNK-9L →	+0.674	+1.414	.034	.008	1	1
LUNG_SCLC	PF-562271 →	+0.964	+1.414	.016	.008	1	1
LUNG_SCLC	HG6-64-1 →	+1.500	+1.414	.018	.008	1	1

Each partner links to its Q-omics profile. Showing the 6 strongest associations by consensus.

FS106 by Thyroid gland development activity — LUNG_SCLC

Explore this box plot interactively →